Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...
The Obesity Drug Gold Rush: Healthcare Breakthrough or Market Frenzy? The global pharmaceutical industry is witnessing an unprecedented surge in demand for obesity therapies, transforming what was onc...
